Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) and Onconetix (NASDAQ:ONCO – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.
Earnings and Valuation
This table compares Agios Pharmaceuticals and Onconetix’s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Agios Pharmaceuticals | $26.82 million | 91.82 | -$352.09 million | ($6.32) | -6.86 |
Onconetix | $60,000.00 | 58.43 | -$37.41 million | N/A | N/A |
Onconetix has lower revenue, but higher earnings than Agios Pharmaceuticals.
Volatility & Risk
Institutional and Insider Ownership
23.9% of Onconetix shares are held by institutional investors. 4.9% of Agios Pharmaceuticals shares are held by insiders. Comparatively, 19.5% of Onconetix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Agios Pharmaceuticals and Onconetix’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Agios Pharmaceuticals | -1,199.26% | -41.41% | -36.36% |
Onconetix | N/A | -1,472.15% | -68.32% |
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Agios Pharmaceuticals and Onconetix, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Agios Pharmaceuticals | 0 | 2 | 2 | 0 | 2.50 |
Onconetix | 0 | 0 | 0 | 0 | N/A |
Agios Pharmaceuticals currently has a consensus target price of $50.67, indicating a potential upside of 16.80%. Given Agios Pharmaceuticals’ higher possible upside, analysts plainly believe Agios Pharmaceuticals is more favorable than Onconetix.
Summary
Agios Pharmaceuticals beats Onconetix on 6 of the 11 factors compared between the two stocks.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
About Onconetix
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.